AstraZeneca to buy China-based Gracell Biotechnologies in $1.2 billion deal

The cash deal aimed at bolstering AstraZeneca#39;s portfolio values U.S.-listed Gracell at $2 per ordinary share or $10 per ADS of Gracell, plus a non-tradable contingent value right of $0.30 per ordinary share, if certain regulatory milestones are met.

Read More

Top 100 Best Sellers

​ The cash deal aimed at bolstering AstraZeneca#39;s portfolio values U.S.-listed Gracell at $2 per ordinary share or $10 per ADS of Gracell, plus a non-tradable contingent value right of $0.30 per ordinary share, if certain regulatory milestones are met. The cash deal aimed at bolstering AstraZeneca#39;s portfolio values U.S.-listed Gracell at $2 per ordinary share or $10 per ADS of Gracell, plus a non-tradable contingent value right of $0.30 per ordinary share, if certain regulatory milestones are met.  Moneycontrol Latest News Read More